SHEPHERD uses a proprietary software, DELVE, that combines deep learning artificial intelligence and proprietary algorithms with traditional quantitative and qualitative statistical analysis. We start by mapping the mutational landscape (every known target and pathway) of every rare cancer, then add in significant qualitative variables related to patient profile, environmental data, and demographics to inform the best treatment modality.Ã, Our ability to identify target overlap, combined with our deep knowledge of each cancer, allows us to engineer an optimal therapeutic combination and delivery technology for multiple rare cancers